Pro-Pharmaceuticals Starts Colorectal Cancer Trial
Posted on: Monday, 27 November 2006, 12:00 CST
Pro-Pharmaceuticals has started a phase II colorectal cancer trial with its drug Davanat in combination with other chemotherapies.
The phase II trial will examine Davanat with Avastin, 5-Fluorouracil (5-FU) and Leucovorin in patients with locally advanced colorectal cancer who are unable to tolerate intensive chemotherapy with an endpoint of tumor shrinkage.
"Davanat is the first of a new class of drugs based on carbohydrate chemistry," said David Platt, CEO of Pro-Pharmaceuticals. "When we combine the results from this front-line trial, with the very positive results from our phase I/II trials of end stage cancer patients, we believe it will conclusively prove the efficacy enhancing affect and toxicity reduction of Davanat when co-administered with chemotherapeutics and biologics to treat cancer."
Pro-Pharmaceuticals is currently enrolling patients in two first-line phase II cancer trials and expects preliminary results in the first quarter of 2007.
Pro-Pharmaceuticals is engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases. At present, the company's product pipeline is principally focused on increasing the efficacy and decreasing the toxicity of approved chemotherapy drugs.
Source: Datamonitor
Related Articles
- Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
- Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
- Hollis-Eden Pharmaceuticals Initiates Phase I/II Rheumatoid Arthritis Trial
- Biothera Initiates Phase Ib/IIa Clinical Trial With Imprime PGG and Erbitux in Metastatic Colorectal Cancer Patients
- Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
- Somaxon Pharmaceuticals' SILENOR(TM) Demonstrates Positive Results in Its Third Phase 3 Clinical Trial in Insomnia
- Manhattan Pharmaceuticals Expands Phase 2a Obesity Clinical Trial Sites to US
- Somaxon Pharmaceuticals' SILENOR(TM) Demonstrates Positive Results in a Phase 3 Transient Insomnia Clinical Trial
- SGX Pharmaceuticals Discontinues Phase II/III Clinical Trial of Troxatyl in Third-Line Acute Myelogenous Leukemia
- Pro-Pharmaceuticals Presents Phase II/III Clinical Trials at the Central European Society for Anti-Cancer Drug Research Conference
 |
 |
User Comments (0)
RSS Feeds